Please cite this article in press as: Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014), http://dx. doi. org/10. 1016/j. bbr. 2014. 07. 016ARTICLE IN PRESSG Model BBR 9035 1-22 16 A. L. Halberstadt / Behavioural Brain Research xxx (2014) xxx-xxx [97] Smith RL, Barrett RJ, Sanders-Bush E. Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice. Psychopharmacology (Berl) 2003;166:61-8. [98] Benneyworth MA, Smith RL, Barrett RJ, Sanders-Bush E. Complex discrimi-native stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice. Psychopharmacology (Berl) 2005;179:854-62. [99] Winter JC, Rice KC, Amorosi DJ, Rabin RA. Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav 2007;87:472-80. [100] Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible media-tion by serotonin 5-HT 1Aand 5-HT 2Areceptors in rodents. Pharmacol Biochem Behav 2008;88:358-65. [101] Li JX, Rice KC, France CP. Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. J Pharmacol Exp Ther 2008;324:827-33. [102] Gatch MB, Forster MJ, Janowsky A, Eshleman AJ. Abuse liability proﬁle of three substituted tryptamines. J Pharmacol Exp Ther 2011;338:280-9. [103] Appel JB, Cunningham KA. The use of drug discrimination procedures to char-acterize hallucinogenic drug actions. Psychopharmacol Bull 1986;22:959-67. [104] Colpaert FC, Niemegeers GJE, Janssen PAJ. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther 1982;221:206-14. [105] Cunningham KA, Appel JB. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psy-chopharmacology (Berl) 1987;91:67-73. [106] Appel JB, Callahan PM. Involvement of 5-HT receptor subtypes in the discrim-inative stimulus properties of mescaline. Eur J Pharmacol 1989;159:41-6. [107] Schreiber R, Brocco M, Millan MJ. Blockade of the discriminative stimulus effects of by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol 1994;264:99-102. [108] Smith RL, Canton H, Barrett RJ, Sanders-Bush E. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT 2Aand 5-HT 2Creceptors. Pharmacol Biochem Behav 1998;61:323-30. [109] Smith RL, Barrett RJ, Sanders-Bush E. Mechanism of tolerance development to 2,5-dimethoxy-4-iodoamphetamine in rats: down-regulation of the 5-HT 2A, but not 5-HT 2C, receptor. Psychopharmacology (Berl) 1999;144:248-54. [110] May JA, Sharif NA, Chen HH, Liao JC, Kelly CR, Glennon RA, et al. Phar-macological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine]. Pharmacol Biochem Behav 2009;91:307-14. [111] Eckler JR, Rabin RA, Winter JC. Nefazodone in the rat: mimicry and antag-onism of [-]-DOM-induced stimulus control. Pharmacol Biochem Behav 2003;75:405-10. [112] Winter JC, Eckler JR, Rabin RA. Serotonergic/glutamatergic interactions: the effects of m Glu2/3 receptor ligands in rats trained with LSD and PCP as dis-criminative stimuli. Psychopharmacology (Berl) 2004;172:233-40. [113] Marona-Lewicka D, Thisted RA, Nichols DE. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology (Berl) 2005;180:427-35. [114] Gresch PJ, Barrett RJ, Sanders-Bush E, Smith RL. 5-Hydroxytryptamine (serotonin) 2Areceptors in rat anterior cingulate cortex mediate the discrim-inative stimulus properties of d-lysergic acid diethylamide. J Pharmacol Exp Ther 2007;320:662-9. [115] Fiorella D, Rabin RA, Winter JC. The role of the 5-HT 2Aand 5-HT 2Creceptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl) 1995;121:347-56. [116] Glennon RA, Mc Kenney JD. Site-selective 5-HT agonists as discriminative stimuli. Pharmacologist 1985;27:194. [117] Glennon RA, Titeler M, Young R. Structure-activity relationships and mech-anism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol Bull 1986;22:953-8. [118] Marona-Lewicka D, Nichols DE. Further evidence that the delayed tempo-ral dopaminergic effects of LSD are mediated by a mechanism different than the ﬁrst temporal phase of action. Pharmacol Biochem Behav 2007;87: 453-61. [119] Marona-Lewicka D, Chemel BR, Nichols DE. Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl) 2009;203:265-77. [120] Winter JC, Rabin RA. Interactions between serotonergic agonists and antago-nists in rats trained with LSD as a discriminative stimulus. Pharmacol Biochem Behav 1988;30:617-24. [121] Arnt J. Characterization of the discriminative stimulus properties induced by 5-HT 1and 5-HT 2agonists in rats. Pharmacol Toxicol 1989;64:165-72. [122] Reissig CJ, Eckler JR, Rabin RA, Winter JC. The 5-HT 1Areceptor and the stimulus effects of LSD in the rat. Psychopharmacology (Berl) 2005;182:197-204. [123] Appel JB, West WB, Buggy J. LSD, 5-HT (serotonin), and the evolution of a behavioral assay. Neurosci Biobehav Rev 2004;27:693-701. [124] Glennon RA, Titeler M, Lyon RA, Sluster RM. N,N-Di-n-propylseroton binding at serotonin binding sites a comparision with 8-hydroxy-2-(di-n-propylamino)tetralin. J Med Chem 1988;31:867-70. [125] Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen thatinduces stimulus control via 5-HT1A receptors. Pharmacol. Biochem Behav 2000;65:75-82. [126] Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, et al. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 2006;83:122-9. [127] Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron ﬁring by pramipexole, a dopamine D3 receptor-preferring ago-nist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312:35-44. [128] Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M. Agonist activity of LSD and lisuride at cloned 5HT 2Aand 5HT 2Creceptors. Psychopharmacology (Berl) 1998;136:409-14. [129] Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine 1Areceptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology (Berl) 2002;164:93-107. [130] Millan MJ, Maioﬁss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoamin-ergic receptor I. A multivariate analysis of the binding properties of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804. [131] Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, et al. Agonist-directed trafﬁcking of signaling at serotonin 5-HT 2A, 5-HT 2Band 5-HT 2CVSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 2008;594:32-8. [132] Herrmann WM, Horowski R, Dannehl K, Kramer U, Lurati K. Clinical effective-ness of lisuride hydrogen maleate: a double-blind trial versus methysergide. Headache 1977;17:54-60. [133] Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, et al. Effective-ness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. J Endocrinol Invest 1980;3:405-14. [134] Raffaelli Jr E, Martins OJ, dos Santos P, Dãgua Filho A. Lisuride in cluster headache. Headache 1983;23:117-21. [135] Bene ˇs H, Deissler A, Rodenbeck A, Engfer A, Kohnen R. Lisuride treatment of Restless Legs Syndrome: ﬁrst studies with monotherapy in de novo patients and in combination with levodopa in advanced disease. J Neural Transm 2006;113:87-92. [136] White FJ, Appel JB. Lysergic acid diethylamide (LSD) and lisuride: differenti-ation of their neuropharmacological actions. Science 1982;216:535-7. [137] Glennon RA, Hauck AE. Mechanistic studies on DOM as a discriminative stim-ulus. Pharmacol Biochem Behav 1985;23:937-41. [138] Fiorella D, Rabin RA, Winter JC. Role of 5-HT 2Aand 5-HT 2Creceptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false posi-tives. Psychopharmacology (Berl) 1995;121:357-63. [139] Appel JB, West WB, Rolandi WG, Alici T, Pechersky K. Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav 1999;64:353-8. [140] Holohean AM, White FJ, Appel JB. Dopaminergic and serotonergic medi-ation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 1982;81:595-602. [141] Callahan PM, Appel JB. Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug dis-crimination procedure. Psychopharmacology (Berl) 1990;100:13-8. [142] Glennon RA. Discriminative stimulus properties of hallucinogens and related designer drugs. NIDA Res Monogr 1991;116:25-44. [143] Corne SJ, Pickering RW. A possible correlation between drug-induced hallu-cinations in man and a behavioural response in mice. Psychopharmacologia 1967;11:65-78. [144] Silva MT, Calil HM. Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia 1975;42:163-71. [145] Darmani NA, Martin BR, Pandey U, Glennon RA. Do functional relation-ships exist between 5-HT 1Aand 5-HT 2receptors? Pharmacol Biochem Behav 1990;36:901-6. [146] Yamamoto T, Ueki S. Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice. Eur J Pharmacol 1975;32:156-62. [147] Bedard P, Pycock CJ. Wet-dog shake behavior in the rat: a possible quanti-tative model of central 5-hydroxytryptamine activity. Neuropharmacology 1977;16:663-70. [148] Corne SJ, Pickering RW, Warnet BT. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol Chemother 1963;20:106-20. [149] Matthews WD, Smith CD. Pharmacological proﬁle of a model for central sero-tonin receptor activation. Life Sci 1980;26:1397-403. [150] Singleton C, Marsden CA. Circadian variation in the head twitch response pro-duced by 5-methoxy-N1 N1-dimethyltryptamine and p-chloroamphetamine in the mouse. Psychopharmacology (Berl) 1981;74:173-6. [151] Yamaguchi K, Nabeshima T, Ishikawa K, Yoshida S, Kameyama T. Phencyclidine-induced head-weaving and head-twitch through interaction with 5-HT1 and 5-HT2 receptors in reserpinized rats. Neuropharmacology 1987;26:1489-97. [152] Halberstadt AL, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl) 2013;227:727-39. [153] Gazzaley A, Rissman J, Cooney J, Rutman A, Seibert T, Clapp W, et al. Functional interactions between prefrontal and visual association cortex contribute1527 15281529153015311532153315341535153615371538153915401541154215431544154515461547154815491550155115521553155415551556155715581559156015611562156315641565156615671568156915701571157215731574157515761577157815791580158115821583158415851586158715881589159015911592159315941595159615971598159916001601160216031604160516061607160816091610161116121613 1614161516161617161816191620162116221623162416251626162716281629163016311632163316341635163616371638163916401641164216431644164516461647164816491650165116521653165416551656165716581659166016611662166316641665166616671668166916701671167216731674167516761677167816791680168116821683168416851686168716881689169016911692169316941695169616971698